Rehovot, Israel and Munich, Germany – [February 11, 2026] 

Evogene Ltd. (Nasdaq/TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries 
Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders
LMU University Hospital Munich, today announced a collaboration aiming to accelerate the development of novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The collaboration brings together Evogene, Systasy, and Prof. Christoph Klein (LMU University Hospital in collaboration with the German Center for Child and Adolescent Health), with additional participation from the Weizmann Institute of Science in Rehovot, Israel. The program is supported by a prestigious pan-European EUREKA grant, which was awarded to advance this international drug discovery effort. 

Hundreds of millions of people worldwide are affected by inflammatory and immune-mediated diseases in which neutrophils play a key pathogenic role1,2 . Despite being first responders in inflammation and key drivers of tissue damage, neutrophils are not directly targeted by existing therapies, creating a significant unmet need for safe, selective, and effective new treatment approaches.  

The collaboration builds on Prof. Klein’s clinical and scientific studies and insights derived from a rare genetic immunodeficiency. His team identified a novel inborn error of immunity associated with reduced numbers of neutrophil granulocytes, yet without marked functional defects of the immune system. By translating this naturally occurring rare condition into a therapeutic strategy, the collaboration aims to develop targeted therapies that modulate excessive neutrophil driven inflammation while potentially minimizing safety risks commonly associated with immune suppression. 

The collaboration partners contribute complementary and synergistic expertise and technologies. Evogene will lead the small-molecule drug discovery effort using its proprietary ChemPass AI™ generative engine to design, optimize, and prioritize novel inhibitors. Together with the Weizmann Institute of Science, computational design will be tightly integrated with high-throughput experimental validation. Systasy will leverage its proprietary DNA barcoding technology to expand the PathwayProfiler™ platform for multiplexed profiling of stem cell-derived neutrophils, generating high-dimensional functional data to validate and refine Evogene’s AI-designed inhibitors. The Department of Pediatrics at LMU’s Dr. von Hauner Children’s Hospital, led by Prof. Christoph Klein, will apply advanced stem cell biology and  precision diagnostics to validate lead compounds in innovative human in vitro neutrophil models, while also supporting biomarker discovery and translational strategies aimed at personalized immunology and future clinical development.

We are excited to join forces with Systasy’s and Prof. Klein’s scientific expertise inlaunching this international effort, bringing therapeutic solutions to inflammatory conditions affecting many.The support of the prestigious EUREKA grant is a strongvote of confidence in this synergistic collaboration, as well as further acknowledgment of the uniqueness of ChemPass AI™, Evogene’s AI-driven tech engine for small molecule discovery and optimization.By integrating AI-driven discovery with experimental excellence and clinical insight, we aimto advance innovative therapeutic concepts with clear clinical and commercial potential.
Mr. Ofer Haviv, Evogene’s President and CEO.

This EUREKA-funded collaboration marks a pivotal step for Systasy in extending our pathwayProfilerassay platform to neutrophil biology. Partnering with Evogene’s AI innovation, LMU’s clinical expertise, and Weizmann’s validation strengths positions us to deliver breakthrough therapies addressing unmet needs in hyper-inflammatory diseases. Our hyper-multiplexed, patient-derived assays will provide the high-quality functional data essential for accelerating discovery and ensuring translational success.
Dr. Sven Wichert, CEO of Systasy Bioscience GmbH

We care for children with rare diseases every day; occasionally, we discover novel genetic defects and elucidate pathomechanisms. Only rarely, however, is clinical and scientific knowledge translated into the development of novel therapeutic strategies. Thanks to the EUREKA-funded grant, we are now in the privileged position to advance the field substantially.
Prof. Christoph Klein, Chair, Department of Pediatrics, LMU University Hospital